CD8A and neoplasm: Inhibition of critical immune checkpoints (ICIs) leads to enhanced anti-tumor immunity and suppressed tumor growth by enhancing CD8+ tumor infiltrating T cells (TILs) and decreasing regulatory T cells (Tregs) in the tumor microenvironment.